title: Propranolol in the treatment of problematic infantile hemangioma: review of 35 consecutive patients from a vascular anomalies clinic.
abstract: BACKGROUND
  Propranolol, a nonselective β-blocker, has been reported as efficient for controlling the growth of complicated infantile hemangiomas (IHs). No uniformly accepted protocol exists regarding the administration of oral propranolol for IH.
  
  
  OBJECTIVE
  We sought to share our experience using propranolol for problematic IH and to evaluate the efficacy of this treatment modality.
  
  
  METHODS
  A retrospective chart review analysis was performed for 35 consecutive children treated with propranolol as an oral solution on an outpatient basis in our dermatology/vascular anomalies clinic. A protocol was established with the help of our pediatric cardiologists, including pretreatment electrocardiography and echocardiography. Medical photographs taken after 2 months of treatment were rated by two independent evaluators.
  
  
  RESULTS
  We treated 31 girls and 4 boys with a median age of 3.5 months. Rapid improvement was reported in the first days of treatment in 34 patients. Mean improvement after 2 months was 61.5%. No serious adverse effects were reported.
  
  
  CONCLUSIONS
  Propranolol was effective in controlling the proliferative phase of problematic IH. It was well tolerated in our study. Outpatient treatment is possible if parents follow strict guidelines. Propranolol should be a first-line treatment for problematic IH in carefully selected patients.
authors.affiliation: Division of Dermatology, Department of Medicine, CHU University of Montreal, Montreal, QC.
authors.forename: Janie
authors.initials: J
authors.lastname: Bertrand
authors.forename: Rita
authors.initials: R
authors.lastname: Sammour
authors.forename: Catherine
authors.initials: C
authors.lastname: McCuaig
authors.forename: Josée
authors.initials: J
authors.lastname: Dubois
authors.forename: Afshin
authors.initials: A
authors.lastname: Hatami
authors.forename: Sandra
authors.initials: S
authors.lastname: Ondrejchak
authors.forename: Christine
authors.initials: C
authors.lastname: Boutin
authors.forename: Patricia
authors.initials: P
authors.lastname: Bortoluzzi
authors.forename: Louise C
authors.initials: LC
authors.lastname: Laberge
authors.forename: Julie
authors.initials: J
authors.lastname: Powell
mesh_terms: D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D018579:Patient Selection; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol